Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three clinical trials for Opdivo in combination with other drugs ...
Bristol-Myers Squibb Company BMY was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the ...
CHICAGO, Sept. 14, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CLF, HTZ, JWN, and OCLR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's …
4-Traders · 8mon
Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to Opdivo's clinical setbacks in ...
Pharmaceutical stocks were in the limelight this week with Merck's MRK CEO Ken Frazier resigning from President Donald Trump’s manufacturing council. The sector was also in the news with an investigation being launched into the rising prices of multiple ...
The third-quarter earnings season is off to a strong start. The results of the companies that have reported numbers show that earnings and revenue growth pace is accelerating from the first two quarters. In particular, revenue growth has shown significant ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and Bristol-Myers (BMY). These research reports have been ...
Yahoo! · 6mon